Assessment of glypican-3 immune expression in ameloblastoma, ameloblastic fibroma, ameloblastic carcinoma (pilot study)
Tóm tắt
Odontogenic tumors a variety of benign and malignant lesions developed exclusively in the jaws. They are known to have variable clinical behaviors and different histological features. The development of odontogenic tumors is attributed to alterations in some genetic and biological molecules. The aim of this study is to assess Glypican-3 immune expression in different groups of odontogenic neoplasms as in Ameloblastoma, Ameloblastic Fibroma, and Ameloblastic Carcinoma, and compare it to dental follicle tissue as control group. Also correlate the marker expression with the known biological behavior of these tumors. This study included 40 cases were selected from oral and maxillofacial pathology department (ten cases in each group). Some sections are prepared to be stained with H&E stain and other sections with Glypican-3 immune stain. Histological examination and Histomorphometric analysis were done finally under light microscope. The area percents of Glypican-3 immune expression in all tumor sections were measured. Level of expression of Glypican-3 revealed significant difference between the study groups (P-value < or = 0.05). The level of immune expression was highest in ameloblastic carcinoma group (M = 58.7) followed by ameloblastoma group (M = 33.9), then ameloblastic fibroma (M = 5.6) and lowest in the control group of dental follicle (M = 1.3). Glypican-3 immune expression demonstrated statistically significant difference among the study groups, indicating that it may have contributing role in tumor pathogenesis and its biological behavior.
Từ khóa
Tài liệu tham khảo
Al-aroomy L, Wali M, Alwadeai M, El Desouky E, Amer H (2022) Odontogenic tumors: a retrospective study in Egyptian population using WHO 2017 classification. Medicina Oral Patologia Oral y Cirugia Bucal 27(3):e198. https://doi.org/10.4317/medoral.24661
Jordan RC, Speight PM (2009) Current concepts of odontogenic tumors. Diagn Histopathol 15(6):303–310. https://doi.org/10.1016/j.mpdhp.2009.03.002
EI-Naggar AK. WHO classification of head and neck tumors. International Agency; 2017.
Carroll C, Gill M, Bowden E, O’Connell JE, Shukla R, Sweet C (2019) Ameloblastic Fibroma of the mandible reconstructed with autogenous parietal bone: report of a case and literature review. Case Rep Dent. https://doi.org/10.1155/2019/5149219
Kruse AL, Zwahlen RA, Grätz KW (2009) New classification of maxillary ameloblastic carcinoma based on an evidence-based literature review over the last 60 years. Head Neck Oncol 1(1):1–7. https://doi.org/10.1186/1758-3284-1-31
Braimah R, Uguru C, Ndukwe K (2017) Ameloblastic carcinoma of the jaws: Review of the literature. J Dent Allied Sci 6(2):70–73. https://doi.org/10.4103/jdas.jdas_4_17
Raoufi-Danner S, Carl S, Jahan A (2018) Oral rehabilitation of patients with ameloblastoma of the mandible. Clinical results in three patients with different bone reconstruction techniques. Open Dent J 1:1. https://doi.org/10.2174/1874210601812011107
Capurro MI, Xu P, Shi W, Li F, Jia A, Filmus J (2008) Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell 14(5):700–711. https://doi.org/10.1016/j.devcel.2008.03.006
Andisheh-Tadbir A, Goharian AS, Ranjbar MA (2020) Glypican-3 expression in patients with oral squamous cell carcinoma. J Dent 21(2):141. https://doi.org/10.30476/DENTJODS.2019.84541.1089
Feng M, Ho M (2014) Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett 588(2):377–382. https://doi.org/10.1016/j.febslet.2013.10.002
Andisheh-Tadbir A, Ashraf MJ, Gudarzi A, Zare R (2019) Evaluation of Glypican-3 expression in benign and malignant salivary gland tumors. J Oral Biol Craniofac Res 9(1):63–66. https://doi.org/10.1016/j.jobcr.2018.09.002
Mendes RB, Dias RB, Figueiredo AL, Gurgel CA, Santana Filho M, Melo LA, Trierveiler M, Cury PR, Leonardi R, Dos Santos JN (2017) Glypican-3 distinguishes aggressive from non-aggressive odontogenic tumors: a preliminary study. J Oral Pathol Med 46(4):297–300. https://doi.org/10.1111/jop.12501
Chen CP (2012) Prenatal findings and the genetic diagnosis of fetal overgrowth disorders: Simpson-Golabi-Behmel syndrome, Sotos syndrome, and Beckwith-Wiedemann syndrome. Taiwan J Obstet Gynecol 51(2):186–191. https://doi.org/10.1016/j.tjog.2012.04.004
Saleh HA, Makawi DM, Rashad AE (2023) Immunohistochemical assessment of the potential behavior of glandular odontogenic cyst and inflammatory periodontal cyst using E-cadherin and N-cadherin. Beni-Suef Univ J Basic Appl Sci 12(1):97. https://doi.org/10.1186/s43088-023-00439-9
Santosh AB, Jones TJ (2014) The epithelial-mesenchymal interactions: insights into physiological and pathological aspects of oral tissues. Oncol Rev 8(1):239. https://doi.org/10.4081/oncol.2014.239
Ho M, Kim H (2011) Glypican-3: a new target for cancer immunotherapy. Eur J Cancer 47(3):333–338. https://doi.org/10.1016/j.ejca.2010.10.024
Chaturvedi TP, Gupta K, Agrawal R, Kumar PN, Gupta J (2022) Immunohistochemical expression of Ki-67 and Glypican-3 to distinguish aggressive from nonaggressive benign odontogenic tumors. J Cancer Res Ther 18(Suppl 2):S205–S209
Ng A, Wong M, Viviano B, Erlich JM, Alba G, Pflederer C, Jay PY, Saunders S (2009) Loss of glypican-3 function causes growth factor-dependent defects in cardiac and coronary vascular development. Dev Biol 335(1):208–215. https://doi.org/10.1016/j.ydbio.2009.08.029
Matsuo I, Kimura-Yoshida C (2013) Extracellular modulation of Fibroblast Growth Factor signaling through heparan sulfate proteoglycans in mammalian development. Curr Opin Genet Dev 23(4):399–407. https://doi.org/10.1016/j.gde.2013.02.004
Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T (2019) Next-generation cancer immunotherapy targeting glypican-3. Front Oncol 9:248. https://doi.org/10.3389/fonc.2019.00248